Litigation Details for AZURITY PHARMACEUTICALS, INC. v. BIONPHARMA INC. (D.N.J. 2021)
✉ Email this page to a colleague
AZURITY PHARMACEUTICALS, INC. v. BIONPHARMA INC. (D.N.J. 2021)
| Docket | ⤷ Try a Trial | Date Filed | 2021-06-22 |
| Court | District Court, D. New Jersey | Date Terminated | 2021-09-10 |
| Cause | Assigned To | Michael Andre Shipp | |
| Jury Demand | Referred To | Douglas Arpert | |
| Patents | 10,039,745; 10,154,987; 6,028,222; 6,031,007; 6,977,257; 8,008,006; 8,568,747; 8,778,366; 9,000,011; 9,463,183; 9,616,096; 9,669,008; 9,808,442; 9,855,214; 9,968,553 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in AZURITY PHARMACEUTICALS, INC. v. BIONPHARMA INC.
The small molecule drugs covered by the patents cited in this case are ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , and ⤷ Try a Trial .
Biologic Drugs cited in AZURITY PHARMACEUTICALS, INC. v. BIONPHARMA INC.
The biologic drug covered by the patents cited in this case is ⤷ Try a Trial .
Details for AZURITY PHARMACEUTICALS, INC. v. BIONPHARMA INC. (D.N.J. 2021)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2021-08-23 | 29 | -1067, which relates to asserted U.S. Patent No. 10,154,987, should also be included herein with …Judge Stark's Revised Procedures fo r Managing Patent Cases (which is posted at 1 …www.ded.uscourts.gov; see Chambers, Judge Leonard P. Stark, Patent Cases), and the parties having determined…Identification of Accused Product(s) and Asserted Patent(s). By December… and the asserted patent(s) they alleged infringe, and produce the | External link to document | |
| 2021-08-27 | 45 | Reply Brief to Opposition to Motion | Shrestha Decl. Ex. M) ’745 patent U.S. Patent No. 10,039,745 B2 (ECF No. 9-5, 7/13/21… Decl. Ex. C) ’023 patent or patent-in-suit U.S. Patent No. 11,040,023 B2 (ECF No. 1-1,…PTO or Patent Office United States Patent and Trademark Office Second Wave Patents …the ’023 patent is “patentably indistinct” from the claims of the First and Second Wave Patents, which… ’023 patent are patentably indistinct from the claims of the First and Second Wave Patents, which | External link to document |
| 2021-08-27 | 46 | of U.S. Patent Nos. 9,669,008 (“the ’008 patent”); 9,808,442 (“the ’442 patent”); 10,039,745 (“the ’… ’745 patent”); and 10,154,987 (“the ’987 patent”) (collectively, “patents-in-suit”). Bionpharma has…II. The Patents-in-Suit. A. The ’008 Patent. The ‘008 patent, entitled …assignee on the face of the patent. The patent issued with 20 claims. ’008 patent at cover. …assignee on the face of the patent. The patent issued with 30 claims. ’442 patent at cover. The | External link to document | |
| 2021-10-01 | 60 | Redacted Document | 10,154,987 ’745 Patent U.S. Patent No. 10,039,745 ’868 Patent U.S. Patent No. 10,772,868…ABBREVIATIONS ’023 Patent U.S. Patent No. 11,040,023 ’008 Patent U.S. Patent No. 9,669,…9,669,008 ’442 Patent U.S. Patent No. 9,808,442 ’987 Patent U.S. Patent No. 10,154,987…10,772,868 ’482 Patent U.S. Patent No. 10,786,482 ’621 Patent U.S. Patent No. 10,918,621…to U.S. Patent Application No. 15/081,603 (now U.S. Patent No. 9,669,008, or “the ’008 Patent”). D.I | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
